Maternal Serum Quad Screen : 30294

Message
The Quad Screen in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Quad Screen results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down syndrome or trisomy 18.


The following information must be provided for interpretation of results: Maternal date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, neural tube defect history, and cigarette smoker status.

Please submit completed Maternal Patient History Form. See link in Additional Infomation.
Please use Internet Explorer. Links in additional information are not supported by Chrome.

Test Code
MATQSQ or 30294

Alias/See Also
Quad Screen; Maternal Screen

CPT Codes
81511

Includes
Panel includes: AFP, unconjugated Estriol, hCG, Dimeric Inhibin A and Maternal Risk Interpretation.

Instructions
Serum separator tube or plain red.

Transport Container
Centrifuge the serum separator tube and transport. If plain red, centrifuge and aliquot 3 mL serum (Min: 1 mL) into a standard transport tube.

Transport Temperature
Refrigerated.

Specimen Stability
Ambient: 14 days; Refrigerated: 14 days; Frozen: 28 days

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, Gross lipemia.

Methodology
Immunoassay

Setup Schedule
Monday - Saturday

Report Available
3-5 days (From receipt at performing laboratory)

Limitations
Quad Screen results consistent with an increased risk of trisomy should be confirmed with amniotic fluid specimen. Results consistent with increased risk of NTD may be followed-up with appropriate diagnostic testing as detailed in the report. Maternal serum screening yields a low percentage of false negatives. A wide range of other chromosomal abnormalities are not identified by maternal serum screening.

Reference Range
By report.

Clinical Significance
Maternal serum Quad Screen is used for prenatal screening of Down syndrome (Trisomy 21), Trisomy 18 (Edwards syndrome), and open neural tube defects (ONTD). This profile includes alpha-fetaprotein (AFP), unconjugated estriol (µE3), human chorionic gonadotropin (hCG), and inhibin A. Establishing risk for fetal Down syndrome, using the quad screen achieves a 70-75% detection rate with a 5% false positive rate. Screening for Trisomy 18 detects 60% of affected fetuses with a 0.2% false positive rate. MSAFP screening detects 88% of anencephaly and 79% of open spina bifida with a 3% false positive rate. Normal results do not ensure birth of a normal infant. In addition, 2-3% of newborns have some type of physical or mental defect, many of which may be undetectable with current prenatal diagnostic procedures.

Performing Laboratory
Quest Diagnostics

Additional Information
Maternal Patient History Form


The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.